Century Therapeutics, Inc.
IPSC
$2.44
$0.146.09%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -12.57% | -16.13% | |||
| Gross Profit | 12.57% | 16.13% | |||
| SG&A Expenses | -14.05% | -12.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.91% | -15.30% | |||
| Operating Income | 12.91% | 15.30% | |||
| Income Before Tax | 44.11% | -5.78% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.31% | -5.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.31% | -5.78% | |||
| EBIT | 12.91% | 15.30% | |||
| EBITDA | 16.06% | 16.63% | |||
| EPS Basic | 44.84% | -5.51% | |||
| Normalized Basic EPS | 13.46% | 15.22% | |||
| EPS Diluted | 45.10% | -5.26% | |||
| Normalized Diluted EPS | 13.46% | 15.22% | |||
| Average Basic Shares Outstanding | 0.95% | 0.26% | |||
| Average Diluted Shares Outstanding | 0.95% | 0.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||